Cite

HARVARD Citation

    Aimo, A. et al. (n.d.). Rationale for CDR132L, an antisense inhibitor of miR-132, for a novel therapy for ventricular remodelling after myocardial infarction. European heart journal. p. . [Online]. 
  
Back to record